Steris management check

STE · Health Care · Health Care Equipment · CEO Daniel A. Carestio

Filings as of

60
Management score, ranked 322nd of 487 · 38th of 60 in Health Care4 good · 3 to watch · 0 flaggedStrongest: clean books · Weakest: skin in the game · Best and worst run in Health Care →

The seven checks

  • Good

    Have owners done well?

    Beat its chosen peersOwners$121Peers$107

    What $100 became since fiscal 2022

    6767th
    Detail

    $100 invested at the start of fiscal 2022 grew to $121, against $107 for the peer group the company picked itself.

  • Good

    Does pay follow performance?

    Pay rose and fell with returns20222026

    Pay actually paid $100 value, each on its own scale

    8145th
    Detail

    Over 5 years, the CEO's pay actually paid (equity valued at the share price) had a correlation of 0.61 with shareholder return. 1 means pay moved in step; below 0, the opposite way.

  • Watch

    What does the CEO cost owners?

    1.5% of net income

    $11.5m pay · $782.3m net income, FY2026

    0.1%1%3%10%
    3638th
    Detail

    $11.5m of reported pay in fiscal 2026, against $782.3m of net income.

  • Watch

    Do they own the stock?

    CEO stake ≈ 1.3 years of pay

    68,075 shares ≈ $14.4m

    0.1y1y5y20y100y

    6 mo: ▲ $0 bought · ▼ $5.8m sold

    2020th
    Detail

    The CEO holds 68,075 shares, directly or through trusts (unvested awards not counted): about 1.3 years of pay. 6 insiders sold $5.8m in the last six months and none bought. 3 of 9 sales ran on pre-arranged 10b5-1 plans.

  • Good

    Are owners being diluted?

    Share count shrinking2021 · 98m2025 · 99m

    Diluted shares −0.4% a year; flagged above +2%

    0%10%20%

    Stock pay 1.0% of revenue

    5441st
    Detail

    Diluted shares changed -0.4% a year over the last three fiscal years. Stock-based pay was 1.0% of revenue in the latest year.

  • Watch

    Is leadership stable?

    2 CEOs in the pay table

    5 filings under 8-K 5.02 in 3 years

    0101420+

    CEOs: Daniel A. Carestio, Walter M Rosebrough

    6038th
    Detail

    CEOs in the pay table: Daniel A. Carestio, Walter M Rosebrough. 5 filings under 8-K item 5.02 (officers or directors leaving or joining, or new pay arrangements) in the last 3 years.

  • Good

    Are the books clean?

    No red flags on file

    Since 2021

    • 0Restated
    • 0Auditor changes
    • 0Late filings
    • 010-K amended
    100100th
    Detail

    No restatements, auditor changes or late filings since 2021.

  • Reading the scores

    Each check scored 0–100 from its own figure. The tick is the Health Care median; the ordinal is the share of ranked S&P 500 companies it matches or beats.

    Hover a chart for its figures. Detail has the full reading.

Pay versus performance

From the proxy statement filed June 11, 2026.

CEO pay as reportedActually paid ⓘWhat $100 becamePeer group the company chose
$0$7.1m$14.1m$10020222023202420252026$121$107

Pay tied most to Adjusted EBIT

Other key measuresAdjusted Free Cash Flow

Show the figures
Fiscal yearCEOCEO payActually paidOther executives (avg)$100 becamePeersNet income
2026Daniel A. Carestio, Walter M Rosebrough$11.5m$3.3m$2.6m$121$107$782.3m
2025—$10.7m$7.9m$2.6m$123$123$614.6m
2024—$9.6m$14.1m$2.5m$120$115$378.2m
2023—$7.7m$2.2m$2.1m$102$99$107.0m
2022—$5.9m$11.8m$2.4m$128$111$243.9m

Insiders and the CEO's stakeSelling

President and CEO
Daniel A Carestio
Shares held
68,075
At that filing's price
≈ $14.4m
Latest Form 4
Jun 5, 2026

6 insiders sold $5.8m in the last six months and none bought. 3 of 9 sales ran on pre-arranged 10b5-1 plans.

Open-market trades by officers and directors since May 21, 2026.

  • SoldMohsen SohiDirector$2.2mNov 10, 2026
  • SoldKaren L BurtonSr. Vice Pres., CFO$1.5mNov 11, 2026
  • SoldDaniel A CarestioPresident and CEO · 10b5-1 plan$947kJun 5, 2026
  • SoldJulia MadsenSr. VP and GM, Life Sciences$532kNov 13, 2026

Leadership and governance on file

20222023202420252026Leadership 7Votes 6
All 7 filings

Latest shareholder vote results: Aug 6, 2026, including the say-on-pay vote.

Where the money went

2021–2025: $1.8bn returned to owners in buybacks and dividends, 86% of net income, and $272.2m of pay in stock.

Net incomeBuybacksDividendsStock-based payDiluted shares
$0$391.1m$782.3m20212022202320242025Shares98m100m99m99m99m
Show the figures
Fiscal year20212022202320242025
Revenue$4.2bn$4.5bn$5.1bn$5.5bn$5.9bn
Net income$243.9m$107.0m$378.2m$614.6m$782.3m
Stock-based pay$57.7m$39.0m$56.5m$57.4m$61.7m
Buybacks$55.8m$308.6m$11.8m$211.3m$235.5m
Dividends$163.2m$183.5m$200.6m$219.9m$241.8m
Diluted shares98m100m99m99m99m

Educational only, not investment advice. Figures are as filed with the SEC: pay from the proxy's pay-versus-performance table, capital allocation from 10-K XBRL data, insider trades from Form 4s over the last six months, events from the last 5 years of filings. The peer group is the one the company chose. See the method.